Ken Griffin Citadel Advisors
Ken Griffin founded Citadel, one of the world’s largest and most successful hedge funds. Starting his trading career from his Harvard dorm room at a young age, Griffin quickly developed a keen sense for markets and built Citadel into a global powerhouse with billions in assets under management. Known for his quantitative and technology-driven strategies, Griffin has also made headlines for significant philanthropic contributions, supporting causes in education, the arts, and public institutions. Over the years, he has earned recognition as one of the preeminent figures in modern finance.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boeing
BA
|
+$830M |
| 2 |
UnitedHealth
UNH
|
+$769M |
| 3 |
Arthur J. Gallagher & Co
AJG
|
+$691M |
| 4 |
Amazon
AMZN
|
+$654M |
| 5 |
Bank of America
BAC
|
+$634M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.23B |
| 2 |
NVIDIA
NVDA
|
+$550M |
| 3 |
Spotify
SPOT
|
+$473M |
| 4 |
Citigroup
C
|
+$460M |
| 5 |
Boston Scientific
BSX
|
+$428M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 3.13% |
| 2 | Technology | 2.97% |
| 3 | Financials | 2.19% |
| 4 | Consumer Discretionary | 2.09% |
| 5 | Industrials | 1.9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
12776
PUT
Allogene Therapeutics
ALLO
$708M
| $31.7K | ﹤0.01% |
14,900
-25,000
| -63% | -$61.7K |
|
12777
PUT
Dakota Gold
DC
$836M
| $31.7K | ﹤0.01% |
14,400
+600
| +4% | +$1.35K |
|
12778
PUT
GrafTech
EAF
$199M
| $31.7K | ﹤0.01% |
1,830
+70
| +4% | +$1.3K |
|
12779
CALL
iShares MSCI Hong Kong ETF
EWH
$1.21B
| $31.7K | ﹤0.01% |
1,900
-236,800
| -99% | -$4.2M |
|
12780
PUT
Harvard Bioscience
HBIO
$30.3M
| $31.6K | ﹤0.01% |
1,500
+1,290
| +614% | +$29.6K |
|
12781
PUT
Stellus Capital Investment Corp
SCM
$250M
| $31.6K | ﹤0.01% |
2,300
-400
| -15% | -$5.54K |
|
|
TBRG
12782
CALL
DELISTED
TruBridge
TBRG
| $31.6K | ﹤0.01% |
+1,600
| New | +$24.7K |
|
|
XOMA
12783
CALL
DELISTED
Xoma
XOMA
| $31.5K | ﹤0.01% |
1,200
+1,100
| +1,100% | +$32.1K |
|
|
INFN
12784
CALL
DELISTED
Infinera Corporation Common Stock
INFN
| $31.5K | ﹤0.01% |
4,800
-7,100
| -60% | -$47.3K |
|
12785
CALL
Grupo Cibest SA
CIB
$22.8B
| $31.5K | ﹤0.01% |
1,000
-300
| -23% | -$9.66K |
|
12786
PUT
Pediatrix Medical
MD
$2.16B
| $31.5K | ﹤0.01% |
2,400
-1,700
| -41% | -$23.5K |
|
|
AMRN
12787
CALL
Amarin Corp
AMRN
$297M
| $31.5K | ﹤0.01% |
3,245
-440
| -12% | -$4.71K |
|
12788
PUT
Nicolet Bankshares
NIC
$3.75B
| $31.5K | ﹤0.01% |
300
-100
| -25% | -$10.6K |
|
|
GP
12789
CALL
GreenPower Motor Co
GP
$13M
| $31.5K | ﹤0.01% |
4,090
+1,890
| +86% | +$18.8K |
|
12790
PUT
ADC Therapeutics
ADCT
$129M
| $31.4K | ﹤0.01% |
15,800
-15,700
| -50% | -$41.1K |
|
12791
CALL
System1
SST
$24.6M
| $31.4K | ﹤0.01% |
3,500
+1,330
| +61% | +$13.4K |
|
12792
Context Therapeutics
CNTX
$48M
| $31.4K | ﹤0.01% |
+29,900
| New | +$51.7K |
|
12793
PUT
Invesco Taxable Municipal Bond ETF
BAB
$1.01B
| $31.4K | ﹤0.01% |
1,200
-14,500
| -92% | -$388K |
|
12794
PUT
Alto Ingredients
ALTO
$324M
| $31.4K | ﹤0.01% |
20,100
-10,500
| -34% | -$16.5K |
|
12795
CALL
Wheels Up
UP
$182M
| $31.4K | ﹤0.01% |
950
-380
| -29% | -$16K |
|
|
THTX
12796
DELISTED
Theratechnologies
THTX
| $31.3K | ﹤0.01% |
17,317
-20,825
| -55% | -$28.3K |
|
12797
PUT
Betterware México
BWMX
$613M
| $31.3K | ﹤0.01% |
2,800
-11,800
| -81% | -$145K |
|
12798
Hitek Global
HKIT
$28M
| $31.3K | ﹤0.01% |
+6
| New | +$31.1K |
|
12799
PUT
Santander
BSBR
$43.2B
| $31.3K | ﹤0.01% |
8,000
+7,000
| +700% | +$32K |
|
12800
PUT
Anika Therapeutics
ANIK
$288M
| $31.3K | ﹤0.01% |
1,900
+1,800
| +1,800% | +$35.5K |
|
Similar funds
Ken Griffin's Q4 2024 Portfolio in Review
As of Q4 2024, Ken Griffin held 15,826 positions worth $578B, up 11% from $518B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Ken Griffin deployed $35.2B of net new capital in Q4 2024, opening 1,745 new positions and adding to 6,428 existing holdings. Its largest new stake was Zoetis: 1,090,499 shares worth $178M.
By sector, the portfolio is most concentrated in Healthcare at 3.1% of assets, up from 2.9% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was State Street SPDR S&P 500 ETF Trust, an estimated $1.23B trimmed.
- Ken Griffin's largest Q4 2024 buy was Zoetis: 1,090,499 shares worth $178M.
- Ken Griffin added most to Boeing in Q4 2024, an estimated $830M increase.
- Ken Griffin's biggest Q4 2024 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $1.23B.
- Ken Griffin fully exited Spotify in Q4 2024, selling an estimated $473M.
- Ken Griffin's ten largest holdings make up 31% of its $578B portfolio in Q4 2024.
- Ken Griffin opened 1,745 new positions and closed 1,423 in Q4 2024.
- Ken Griffin's portfolio value rose 11% quarter-over-quarter to $578B.
Based on Citadel Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.